Radiation Oncology/Therapy: Page 345

NAS posts mixed results in Q3

By AuntMinnie.com staff writers

A 17% sales increase for its brachytherapy seeds and accessories partially offset a 14% decline in nontherapeutic product sales in North American Scientific's fiscal third quarter (end-July 31).

September 20, 2007

BioLucent spins off breast brachytherapy technology

By AuntMinnie.com staff writers

Mammography pad developer BioLucent of Aliso Viejo, CA, has spun off its SAVI breast brachytherapy technology into an independent company called Cianna Medical, also of Aliso Viejo.

September 19, 2007

Varian, BrainLab team up

By AuntMinnie.com staff writers

Varian Medical Systems of Palo Alto, CA, and image-guided therapy developer BrainLab of Germany have partnered to introduce the Novalis Tx stereotactic radiosurgery system.

September 18, 2007

NAS completes sale of Nomos unit

By AuntMinnie.com staff writers

Radiation therapy developer North American Scientific (NAS) has completed the sale of its Nomos radiation oncology business to Best Medical International.

September 18, 2007

SUV on FDG-PET can predict cervical cancer prognosis

By Shalmali Pal

Historically, age and histology, as well as tumor volume and stage, have been used to predict patient outcome and overall survival for cervical cancer. But a multidisciplinary group from St. Louis-based Washington University School of Medicine has recommended the adoption of tumor uptake on FDG-PET imaging as a better biomarker for outcome and survival.

September 18, 2007

Mathematical models evaluate dynamics of tumor growth, efficacy of combined cancer therapies

Drugs that prevent malignant tumors from developing their own blood supply are attracting considerable interest in clinical oncology. Preclinical studies suggest that anti-angiogenic drugs will have the greatest effect when used in tandem with chemotherapy and/or radiotherapy. The question is: How can these elements combine into the most effective treatment regime?

September 13, 2007

Linac/MRI prototype allows real-time tumor tracking during rad therapy

By Kathlyn Stone

Scientists at the University of Alberta Cross Cancer Institute in Canada are constructing a system that couples a linear accelerator (linac) with an MR scanner that will provide real-time tracking of tumors and healthy tissues during irradiation. The Alberta Cancer Board has received U.S. and international patents for the system, called Advanced Real-Time Adaptive RadioTherapy (ART).

September 13, 2007

Nucletron spins off from Delft

By AuntMinnie.com staff writers

Radiotherapy provider Nucletron of Veenendaal, the Netherlands, announced that it has completed a management buyout from Delft Instruments, and as a result has become an independent company solely dedicated to radiation oncology.

September 12, 2007

US demonstrates cell death after chemo in experimental NHL study

By Shalmali Pal

SAN FRANCISCO - Sonography is proving to be a noninvasive and inexpensive way to measure tumor response to therapy, according to presenters at the Translational Research in Radiation Oncology and Radiology meeting, sponsored by the American Society for Therapeutic Radiology and Oncology (ASTRO).

September 12, 2007

NAS signs deal to sell Nomos unit

By AuntMinnie.com staff writers

Radiation therapy developer North American Scientific (NAS) of Chatsworth, CA, will sell its Nomos Radiation Oncology business to privately held Best Medical International of Springfield, VA.

September 11, 2007

Accuray nets FDA nod for dose calculation tool

By AuntMinnie.com staff writers

Radiotherapy firm Accuray said that its Monte Carlo dose calculation algorithm has received U.S. Food and Drug Administration (FDA) 510(k) clearance.

September 10, 2007

ROI can influence quantitative FDG-PET study results

By Wayne Forrest

PROVIDENCE, RI - As FDG-PET's role in monitoring tumor response to therapy gains popularity, questions have arisen about the reliability of various methods to determine regions of interest (ROI) to measure FDG uptake. Researchers from the University of California, Los Angeles (UCLA) sought to shed some light on the topic in their study to determine the effects of ROI definition on quantitative measurements of tumor FDG uptake.

September 10, 2007

Previous Page

Page 345 of 469

Next Page